| 臺大學術典藏 |
2022-09-15T01:08:59Z |
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC
|
Tan W.L.; Chua K.L.M.; Chia-Chi Lin; Lee V.H.F.; Tho L.M.; Chan A.W.; Ho G.F.; Reungwetwattana T.; Yang J.C.; Kim D.-W.; Soo R.A.; Ahn Y.C.; Onishi H.; Ahn M.-J.; Mok T.S.K.; Tan D.S.W.; Yang F. |
| 臺大學術典藏 |
2022-08-10T02:37:43Z |
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC
|
Tan W.L.; Chua K.L.M.; Lin C.-C.; Lee V.H.F.; Tho L.M.; Chan A.W.; Ho G.F.; Reungwetwattana T.; CHIH-HSIN YANG; Kim D.-W.; Soo R.A.; Ahn Y.C.; Onishi H.; Ahn M.-J.; Mok T.S.K.; Tan D.S.W.; Yang F. |
| 臺大學術典藏 |
2022-08-10T02:37:41Z |
Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial
|
CHIH-HSIN YANG; Mok T.S.K.; Lu S.; Nakagawa K.; Yamamoto N.; Shi Y.-K.; Zhang L.; Soo R.A.; Morita S.; Tamura T. |
| 臺大學術典藏 |
2022-06-27T07:07:47Z |
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer
|
Mok T.S.K.; Wu Y.-L.; CHONG-JEN YU; Zhou C.; Chen Y.-M.; Zhang L.; Ignacio J.; Liao M.; Srimuninnimit V.; Boyer M.J.; Chua-Tan M.; Sriuranpong V.; Sudoyo A.W.; Jin K.; Johnston M.; Chui W.; Lee J.-S. |
| 臺大學術典藏 |
2022-06-27T07:01:36Z |
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
|
Yang J.C.-H.; Sequist L.V.; Geater S.L.; Tsai C.-M.; Mok T.S.K.; Schuler M.; Yamamoto N.; CHONG-JEN YU; Ou S.H.I.; Zhou C.; Massey D.; Zazulina V.; Wu Y.-L. |
| 臺大學術典藏 |
2021-04-23T05:56:31Z |
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC
|
Tan W.L.;Chua K.L.M.;Lin C.-C.;Lee V.H.F.;Tho L.M.;Chan A.W.;Ho G.F.;Reungwetwattana T.;Ychih-Hsin Yang;Kim D.-W.;Soo R.A.;Ahn Y.C.;Onishi H.;Ahn M.-J.;Mok T.S.K.;Tan D.S.W.;Yang F.; Tan W.L.; Chua K.L.M.; Lin C.-C.; Lee V.H.F.; Tho L.M.; Chan A.W.; Ho G.F.; Reungwetwattana T.; YCHIH-HSIN YANG; Kim D.-W.; Soo R.A.; Ahn Y.C.; Onishi H.; Ahn M.-J.; Mok T.S.K.; Tan D.S.W.; Yang F. |
| 臺大學術典藏 |
2021-04-23T05:56:24Z |
Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis
|
Kok P.-S.;Lee K.;Lord S.;Chih-Hsin Yang;Rosell R.;Goto K.;John T.;Wu Y.-L.;Mok T.S.K.;Lee C.K.; Kok P.-S.; Lee K.; Lord S.; CHIH-HSIN YANG; Rosell R.; Goto K.; John T.; Wu Y.-L.; Mok T.S.K.; Lee C.K. |
| 臺大學術典藏 |
2020-05-26T09:27:11Z |
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
|
Fukuoka M;Wu Y.-L;Thongprasert S;Sunpaweravong P;Leong S.-S;Sriuranpong V;Chao T.-Y;Nakagawa K;Chu D.-T;Saijo N;Duffield E.L;Rukazenkov Y;Speake G;Jiang H;Armour A.A;To K.-F;Chih-Hsin Yang;Mok T.S.K.; Fukuoka M; Wu Y.-L; Thongprasert S; Sunpaweravong P; Leong S.-S; Sriuranpong V; Chao T.-Y; Nakagawa K; Chu D.-T; Saijo N; Duffield E.L; Rukazenkov Y; Speake G; Jiang H; Armour A.A; To K.-F; CHIH-HSIN YANG; Mok T.S.K. |
| 臺大學術典藏 |
2020-05-26T09:27:01Z |
Symptom control and quality of life in lux-lung 3: A phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations
|
Chih-Hsin Yang;Hirsh V;Schuler M;Yamamoto N;O'Byrne K.J;Mok T.S.K;Zazulina V;Shahidi M;Lungershausen J;Massey D;Palmer M;Sequist L.V.; CHIH-HSIN YANG; Hirsh V; Schuler M; Yamamoto N; O'Byrne K.J; Mok T.S.K; Zazulina V; Shahidi M; Lungershausen J; Massey D; Palmer M; Sequist L.V. |
| 臺大學術典藏 |
2020-05-26T09:27:01Z |
Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
|
Wu Y.-L;Fukuoka M;Mok T.S.K;Saijo N;Thongprasert S;Chih-Hsin Yang;Chu D.-T;Chih-Hsin Yang;Rukazenkov Y.; Wu Y.-L; Fukuoka M; Mok T.S.K; Saijo N; Thongprasert S; CHIH-HSIN YANG; Chu D.-T; CHIH-HSIN YANG; Rukazenkov Y. |
| 臺大學術典藏 |
2020-05-26T09:26:58Z |
Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III iressa pan-ASia study (IPASS)
|
Chih-Hsin Yang;Wu Y.-L;Chan V;Kurnianda J;Nakagawa K;Saijo N;Fukuoka M;Mcwalter G;Mccormack R;Mok T.S.K.; CHIH-HSIN YANG; Wu Y.-L; Chan V; Kurnianda J; Nakagawa K; Saijo N; Fukuoka M; McWalter G; McCormack R; Mok T.S.K. |
| 臺大學術典藏 |
2020-05-26T09:26:57Z |
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
|
CHIH-HSIN YANG; Sequist L.V; Geater S.L; Tsai C.-M; Mok T.S.K; Schuler M; Yamamoto N; Yu C.-J; Ou S.H.I; Zhou C; Massey D; Zazulina V; Wu Y.-L.; Wu Y.-L.;Zazulina V;Massey D;Zhou C;Ou S.H.I;Yu C.-J;Yamamoto N;Schuler M;Mok T.S.K;Tsai C.-M;Geater S.L;Sequist L.V;Chih-Hsin Yang |
| 臺大學術典藏 |
2020-05-26T09:26:57Z |
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): A phase 3 randomised trial
|
CHIH-HSIN YANG; Ahn M.-J; Wang J; CHIH-HSIN YANG; Lu Y; Atagi S; Ponce S; Lee D.H; Liu Y; Yoh K; Zhou J.-Y; Shi X; Webster A; Jiang H; Mok T.S.K.; Mok T.S.K.;Jiang H;Webster A;Shi X;Zhou J.-Y;Yoh K;Liu Y;Lee D.H;Ponce S;Atagi S;Lu Y;Chih-Hsin Yang;Wang J;Ahn M.-J;Chih-Hsin Yang;Kim S.-W;Nakagawa K;Wu Y.-L;Soria J.-C; Soria J.-C; Wu Y.-L; Nakagawa K; Kim S.-W |
| 臺大學術典藏 |
2020-05-26T09:26:51Z |
A randomized phase 2 study comparing the combination of ficlatuzumab and gefitinib with gefitinib alone in asian patients with advanced stage pulmonary adenocarcinoma
|
Park K.;Close S;Garrus J.E;Payumo F;Komarnitsky P;Han M;Chang G.-C;Chih-Hsin Yang;Tan E.-H;Su W.-C;Geater S.L;Mok T.S.K; Mok T.S.K; Geater S.L; Su W.-C; Tan E.-H; CHIH-HSIN YANG; Chang G.-C; Han M; Komarnitsky P; Payumo F; Garrus J.E; Close S; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:42Z |
Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)
|
Tamura T.;Morita S;Lim W.T;Cheng Y;Ichinose Y;Maemondo M;Chang J;Goto K;Takahashi T;Nishio M;Sugawara S;Chih-Hsin Yang;Soo R.A;Zhang L;Shi Y.K;Yamamoto N;Nakagawa K;Mok T.S.K;Lu S;Nokihara H; Nokihara H; Lu S; Mok T.S.K; Nakagawa K; Yamamoto N; Shi Y.K; Zhang L; Soo R.A; CHIH-HSIN YANG; Sugawara S; Nishio M; Takahashi T; Goto K; Chang J; Maemondo M; Ichinose Y; Cheng Y; Lim W.T; Morita S; Tamura T. |
| 臺大學術典藏 |
2020-05-26T09:26:40Z |
Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
|
Fukuoka M.;Rukazenkov Y;Haddad V;Young H;Mok T.S.K;Yang J.-J;Ichinose Y;Ohe Y;Sunpaweravong P;Chewaskulyong B;Margono B;Han B;Chih-Hsin Yang;Thongprasert S;Saijo N;Wu Y.-L; Wu Y.-L; Saijo N; Thongprasert S; CHIH-HSIN YANG; Han B; Margono B; Chewaskulyong B; Sunpaweravong P; Ohe Y; Ichinose Y; Yang J.-J; Mok T.S.K; Young H; Haddad V; Rukazenkov Y; Fukuoka M. |
| 臺大學術典藏 |
2020-05-26T09:26:38Z |
Targeting RET in patients with RET-rearranged lung cancers: Results from the global, multicenter RET registry
|
Mok T.S.K; CHIH-HSIN YANG; Ou S.-H.I; Pall G; Froesch P; Zalcman G; Gandara D.R; Riess J.W; Velcheti V; Zeidler K; Diebold J; Früh M; Michels S; Monnet I; Popat S; Rosell R; Karachaliou N; Rothschild S.I; Shih J.-Y; Warth A; Muley T; Cabillic F; Mazières J; Drilon A.; Gautschi O;Milia J;Filleron T;Wolf J;Carbone D.P;Owen D;Camidge R;Narayanan V;Doebele R.C;Besse B;Remon-Masip J;Janne P.A;Awad M.M;Peled N;Byoung C.-C;Karp D.D;Van Den Heuvel M;Wakelee H.A;Neal J.W;Mok T.S.K;Chih-Hsin Yang;Ou S.-H.I;Pall G;Froesch P;Zalcman G;Gandara D.R;Riess J.W;Velcheti V;Zeidler K;Diebold J;Fr?h M;Michels S;Monnet I;Popat S;Rosell R;Karachaliou N;Rothschild S.I;Shih J.-Y;Warth A;Muley T;Cabillic F;Mazi?res J;Drilon A.; Gautschi O; Milia J; Filleron T; Wolf J; Carbone D.P; Owen D; Camidge R; Narayanan V; Doebele R.C; Besse B; Remon-Masip J; Janne P.A; Awad M.M; Peled N; Byoung C.-C; Karp D.D; Van Den Heuvel M; Wakelee H.A; Neal J.W |
| 臺大學術典藏 |
2020-05-26T09:26:34Z |
Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): Overall survival and biomarker analyses
|
Soria J.-C.;Thress K.S;Haddad V;Rukazenkov Y;Shi X;Ponce S;Atagi S;Lu Y;Chih-Hsin Yang;Wang J;Ahn M.-J;Yang J.-J;Nakagawa K;Wu Y.-L;Kim S.-W;Mok T.S.K; Mok T.S.K; Kim S.-W; Wu Y.-L; Nakagawa K; Yang J.-J; Ahn M.-J; Wang J; CHIH-HSIN YANG; Lu Y; Atagi S; Ponce S; Shi X; Rukazenkov Y; Haddad V; Thress K.S; Soria J.-C. |
| 臺大學術典藏 |
2020-05-26T09:26:29Z |
Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI
|
Hoyle C.;Chih-Hsin Yang;Mok T.S.K;Mitsudomi T;Bodnar C;Andersohn F;Mann H; Mann H; Andersohn F; Bodnar C; Mitsudomi T; Mok T.S.K; CHIH-HSIN YANG; Hoyle C. |
| 臺大學術典藏 |
2020 |
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC
|
Yang F.; Tan D.S.W; Mok T.S.K; Ahn M.-J; Onishi H; Ahn Y.C; Soo R.A; Kim D.-W; Yang J.C; Reungwetwattana T; Ho G.F; Yang F.;Tan D.S.W;Mok T.S.K;Ahn M.-J;Onishi H;Ahn Y.C;Soo R.A;Kim D.-W;Yang J.C;Reungwetwattana T;Ho G.F;Chan A.W;Tho L.M;Lee V.H.F;Chia-Chi Lin;Chua K.L.M;Tan W.L; Tan W.L; Chua K.L.M; Chia-Chi Lin; Lee V.H.F; Tho L.M; Chan A.W |
| 臺大學術典藏 |
2017 |
Targeting RET in patients with RET-rearranged lung cancers: Results from the global, multicenter RET registry
|
Gautschi O.;Milia J.;Filleron T.;Wolf J.;Carbone D.P.;Owen D.;Camidge R.;Narayanan V.;Doebele R.C.;Besse B.;Remon-Masip J.;Janne P.A.;Awad M.M.;Peled N.;Byoung C.-C.;Karp D.D.;Van Den Heuvel M.;Wakelee H.A.;Neal J.W.;Mok T.S.K.;Yang J.C.H.;Ou S.-H.I.;Pall G.;Froesch P.;Zalcman G.;Gandara D.R.;Riess J.W.;Velcheti V.;Zeidler K.;Diebold J.;Fr?H M.;Michels S.;Monnet I.;Popat S.;Rosell R.;Karachaliou N.;Rothschild S.I.;Jin-Yuan Shih;Warth A.;Muley T.;Cabillic F.;Mazi?Res J.;Drilon A.; Michels S.; Monnet I.; Popat S.; Rosell R.; Karachaliou N.; Rothschild S.I.; JIN-YUAN SHIH; Warth A.; Muley T.; Cabillic F.; Mazi?res J.; Drilon A.; Gautschi O.; Milia J.; Filleron T.; Wolf J.; Carbone D.P.; Owen D.; Camidge R.; Narayanan V.; Doebele R.C.; Besse B.; Remon-Masip J.; Janne P.A.; Awad M.M.; Peled N.; Byoung C.-C.; Karp D.D.; Van Den Heuvel M.; Wakelee H.A.; Neal J.W.; Mok T.S.K.; Yang J.C.H.; Ou S.-H.I.; Pall G.; Froesch P.; Zalcman G.; Gandara D.R.; Riess J.W.; Velcheti V.; Zeidler K.; Diebold J.; Fr?h M. |
| 國立臺灣大學 |
2012 |
BIOMARKER ANALYSES AND OVERALL SURVIVAL (OS) FROM THE RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3, FASTACT-2 STUDY OF INTERCALATED ERLOTINIB WITH FIRST-LINE CHEMOTHERAPY IN ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
|
Mok, T. S. K.; Lee, J. S.; Zhang, L.; Yu, C.; Thongprasert, S.; Ladrera, G. E. I.; Srimuninnimit, V.; Truman, M. I.; Klughammer, B.; Wu, Y. |
| 國立臺灣大學 |
2012 |
TUMOUR BIOMARKER AND PLASMA TIME COURSE DATA FROM ABIGAIL, A PHASE II STUDY OF 1ST-LINE BEVACIZUMAB plus CHEMOTHERAPY IN ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER (NS-NSCLC)
|
Reck, M.; Gorbunova, V. A.; Juhasz, E.; Szima, B.; Orlov, S.; Yu, C.; Pallaud, C.; Scherer, S. J.; Archer, V.; Mok, T. S. K. |
| 國立臺灣大學 |
2012 |
CLINICAL GENOTYPING AND EFFICACY OUTCOMES: EXPLORATORY BIOMARKER DATA FROM THE PHASE II ABIGAIL STUDY OF 1ST-LINE BEVACIZUMAB plus CHEMOTHERAPY IN NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER (NS-NSCLC)
|
Pallaud, C.; Reck, M.; Juhasz, E.; Szima, B.; Yu, C.; Burdaeva, O.; Orlov, S.; Scherer, S. J.; Archer, V.; Mok, T. S. K. |
